<DOC>
	<DOCNO>NCT01938560</DOCNO>
	<brief_summary>As part post-marketing commitment , GSK conduct survey prescribers ' pharmacist ' understanding risk urinary retention retigabine product . This address effectiveness Risk Evaluation Mitigation Strategy ( REMS ) outline REMS approve FDA 10th June 2011 . The objective survey ass prescribers ' pharmacist ' understanding risk urinary retention symptom acute urinary retention potentially associate retigabine use evaluate survey instrument . This cross-sectional study approximately 200 physician ( e.g . neurologists/epileptologists/neurosurgeons ) prescribe retigabine least last 12 month , 200 pharmacist dispense anti-epileptic drug ( AED ) least last 3 month . The primary outcome survey proportion physician pharmacists provide correct response series question concern risk urinary retention symptom acute urinary retention may associate retigabine . The risk capture described retigabine Dear Healthcare Provider ( DHCP ) letter , specifically risk urinary retention .</brief_summary>
	<brief_title>REMS Retigabine Study</brief_title>
	<detailed_description>POTIGA trademark Valeant Pharmaceuticals North America , use GlaxoSmithKline license .</detailed_description>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Able read , speak , understand English . Willing take online survey survey administer via telephone interview , include electronically sign Confidentiality &amp; Consent agreement complete study protocolspecified procedure . Prescribed retigabine within past 12 month ( prescribe physician ) Filled prescription least one AED within previous three month ( pharmacist ) . Physicians pharmacists meeting follow criterion eligible take survey : The physician pharmacist currently employ , representative following : A pharmaceutical company manufacturer medicine healthcare product . Contributor/editor publish guideline committee epilepsy UR . The physician pharmacist visual impairment would prevent able read independently . The physician pharmacist participate Pilot REMS study retigabine . The physician pharmacist employee GSK Concentrics Research .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>